Market Place
Sourcing Support
Foghorn Therapeutics to Participate in 3 Upcoming Investor Conf
12 Nov 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics Provides Q3 2024 Financial Update
04 Nov 2024 //
GLOBENEWSWIRE
Foghorn Doses First Patient With FHD-909 In SMARCA4 Solid Tumors
10 Oct 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics to Participate in the BMO Oncology Summit
01 Oct 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics Appoints Anna Rivkin, Ph.D., as Chief Business Officer
03 Sep 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics To Participate In Two Investor Conferences
28 Aug 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update
08 Aug 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
28 May 2024 //
GLOBENEWSWIRE
Foghorn Raises $110M To Advance Pipeline
22 May 2024 //
GLOBENEWSWIRE
Foghorn Prices Registered Direct Common Stock & Prefunded Warrant Offering
20 May 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
06 May 2024 //
GLOBENEWSWIRE
Foghorn Appoints Kristian Humer as Chief Financial Officer
16 Apr 2024 //
GLOBENEWSWIRE
Foghorn Introduces FHD-909 and EP300 Degrader Oncology Programs at AACR 2024
09 Apr 2024 //
GLOBENEWSWIRE
Foghorn to Participate in Needham`s 23rd Annual Virtual Healthcare Conference
05 Apr 2024 //
GLOBENEWSWIRE
Foghorn to Host Conference Call and Webcast AACR Annual Meeting
26 Mar 2024 //
GLOBENEWSWIRE
Foghorn Provides Financial Update for 2023 and 2024 Strategic Outlook
07 Mar 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting
05 Mar 2024 //
GLOBENEWSWIRE
Foghorn to Participate in Cowen™s 44th Annual Health Care Conference
28 Feb 2024 //
GLOBENEWSWIRE
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
08 Feb 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics Highlights Clinical Program Updates
08 Jan 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics Announces CFO Departure
03 Jan 2024 //
GLOBENEWSWIRE
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286
01 Dec 2023 //
GLOBENEWSWIRE
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
02 Nov 2023 //
GLOBENEWSWIRE
Foghorn to Present at Conferences Including New Preclinical Data from EP300
24 Oct 2023 //
GLOBENEWSWIRE
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286
13 Oct 2023 //
GLOBENEWSWIRE
Foghorn to Present Clinical and Pre-Clinical Data from Multiple Programs
04 Oct 2023 //
GLOBENEWSWIRE
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
05 Sep 2023 //
GLOBENEWSWIRE
Foghorn Announces First Patient Dosed in Phase 1 Combination Study of FHD-286
31 Aug 2023 //
GLOBENEWSWIRE
Foghorn Therapeutics Names Quintás-Cardama Chief Medical Officer
09 Aug 2023 //
CONTRACT PHARMA
Foghorn Therapeutics Announces Chief Medical Officer Succession
08 Aug 2023 //
GLOBENEWSWIRE
Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update
04 Aug 2023 //
GLOBENEWSWIRE
Foghorn sinks eye tumor plans after glimpsing phase 1 data
28 Jun 2023 //
FIERCE BIOTECH
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286
28 Jun 2023 //
GLOBENEWSWIRE
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
07 Jun 2023 //
GLOBENEWSWIRE
Foghorn Announces FDA Has Lifted Clinical Hold on Phase 1 Study of FHD-286
06 Jun 2023 //
GLOBENEWSWIRE
Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update
08 May 2023 //
GLOBENEWSWIRE
Foghorn Therapeutics to Participate at the H.C. Wainwright BioConnect Conference
25 Apr 2023 //
GLOBENEWSWIRE
Foghorn muted as FDA places partial clinical hold on second cancer drug trial
25 Apr 2023 //
FIERCE BIOTECH
Foghorn Therapeutics Provides an Update on FHD-609
24 Apr 2023 //
GLOBENEWSWIRE
Foghorn to Present Preclinical Data from CBP and EP300 Protein Degrader Programs
10 Apr 2023 //
GLOBENEWSWIRE
Foghorn to Highlight Transcription Factor and Protein Degradation Capabilities
06 Apr 2023 //
GLOBENEWSWIRE
Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update
09 Mar 2023 //
GLOBENEWSWIRE
Foghorn Therapeutics Highlights Recent Clinical and Research Progress
09 Jan 2023 //
GLOBENEWSWIRE
Foghorn Therapeutics Announces New Preclinical Data for FHD-286 in AML
05 Dec 2022 //
GLOBENEWSWIRE
Foghorn Therapeutics to Participate at the Evercore ISI HealthCONx Conference
22 Nov 2022 //
GLOBENEWSWIRE
Foghorn to Present at Connective Tissue Oncology Society Annual Meeting
14 Nov 2022 //
GLOBENEWSWIRE
Foghorn to Present New Preclinical Data for BRG1/BRM Inhibitor FHD-286
09 Nov 2022 //
GLOBENEWSWIRE
Foghorn Therapeutics Provides Third Quarter 2022 Financial and Corporate Update
08 Nov 2022 //
GLOBENEWSWIRE
Foghorn Therapeutics Appoints Dr. Thomas J. Lynch, Jr. to Its Board of Directors
27 Oct 2022 //
GLOBENEWSWIRE
Foghorn Announces New Data Demonstrating BRD9 Degradation in Patient
26 Oct 2022 //
GLOBENEWSWIRE
Foghorn to Present at Hanson Wade`s Annual Targeted Protein Degradation Summit
20 Oct 2022 //
GLOBENEWSWIRE
Foghorn to Participate in the Bank of America 2022 Precision Oncology
27 Sep 2022 //
GLOBENEWSWIRE
Foghorn co-founder resigns from board; Guardant and Merck KGaA team up again
01 Sep 2022 //
ENDPTS
Foghorn Therapeutics Announces Change to Board of Directors
31 Aug 2022 //
GLOBENEWSWIRE
Foghorn Shares Tumble After FDA Places Full Hold on Previously Scrutinized Trial
24 Aug 2022 //
BIOSPACE
Foghorn Therapeutics Appoints Lynne Parshall to its Board of Directors
17 Aug 2022 //
GLOBENEWSWIRE
Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update
09 Aug 2022 //
GLOBENEWSWIRE
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
01 Aug 2022 //
GLOBENEWSWIRE
Foghorn Therapeutics Announces Upcoming Investor Conference Participation
31 May 2022 //
GLOBENEWSWIRE
Death triggers FDA hold on Foghorn blood cancer clinical trial
21 May 2022 //
FIERCEBIOTECH
